Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.

Passariello M, D'Alise AM, Esposito A, Vetrei C, Froechlich G, Scarselli E, Nicosia A, De Lorenzo C.

Sci Rep. 2019 Sep 11;9(1):13125. doi: 10.1038/s41598-019-49485-3.

2.

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.

D'Alise AM, Leoni G, Cotugno G, Troise F, Langone F, Fichera I, De Lucia M, Avalle L, Vitale R, Leuzzi A, Bignone V, Di Matteo E, Tucci FG, Poli V, Lahm A, Catanese MT, Folgori A, Colloca S, Nicosia A, Scarselli E.

Nat Commun. 2019 Jun 19;10(1):2688. doi: 10.1038/s41467-019-10594-2.

3.

Longitudinal transcriptomic and genetic landscape of radiotherapy response in canine melanoma.

Giannuzzi D, Marconato L, Elgendy R, Ferraresso S, Scarselli E, Fariselli P, Nicosia A, Pegolo S, Leoni G, Laganga P, Leone VF, Giantin M, Troise F, Dacasto M, Aresu L.

Vet Comp Oncol. 2019 Sep;17(3):308-316. doi: 10.1111/vco.12473. Epub 2019 Mar 27.

PMID:
30805995
4.

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.

Green CA, Sande CJ, Scarselli E, Capone S, Vitelli A, Nicosia A, Silva-Reyes L, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Hutchings CL, Cargill T, Angus B, Klenerman P, Pollard AJ.

J Infect. 2019 May;78(5):382-392. doi: 10.1016/j.jinf.2019.02.003. Epub 2019 Feb 8.

PMID:
30742894
5.

Creamino: A Cost-Effective, Open-Source EEG-Based BCI System.

Chiesi M, Guermandi M, Placati S, Scarselli EF, Guerrieri R.

IEEE Trans Biomed Eng. 2019 Apr;66(4):900-909. doi: 10.1109/TBME.2018.2863198. Epub 2018 Aug 3.

PMID:
30080140
6.

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.

Sasso E, D'Avino C, Passariello M, D'Alise AM, Siciliano D, Esposito ML, Froechlich G, Cortese R, Scarselli E, Zambrano N, Nicosia A, De Lorenzo C.

MAbs. 2018 Oct;10(7):1060-1072. doi: 10.1080/19420862.2018.1496772. Epub 2018 Aug 1.

7.

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.

Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E.

JAMA Oncol. 2018 Aug 1;4(8):1085-1092. doi: 10.1001/jamaoncol.2018.1482.

8.

Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.

Vitelli A, Folgori A, Scarselli E, Colloca S, Capone S, Nicosia A.

Expert Rev Vaccines. 2017 Dec;16(12):1241-1252. doi: 10.1080/14760584.2017.1394842. Epub 2017 Oct 30. Review.

PMID:
29047309
9.

Antibody response to respiratory syncytial virus infection in children <18 months old.

Esposito S, Scarselli E, Lelii M, Scala A, Vitelli A, Capone S, Fornili M, Biganzoli E, Orenti A, Nicosia A, Cortese R, Principi N.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1700-6. doi: 10.1080/21645515.2016.1145847. Epub 2016 Feb 22.

10.

Parallel Solver for Diffuse Optical Tomography on Realistic Head Models With Scattering and Clear Regions.

Placati S, Guermandi M, Samore A, Scarselli EF, Guerrieri R.

IEEE Trans Biomed Eng. 2016 Sep;63(9):1874-1886. doi: 10.1109/TBME.2015.2504178. Epub 2015 Nov 26.

PMID:
26625406
11.

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.

Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, Cortese R, Thompson AJ, Sande CS, de Lara C, Klenerman P, Pollard AJ.

BMJ Open. 2015 Oct 28;5(10):e008748. doi: 10.1136/bmjopen-2015-008748.

12.

A Driving Right Leg Circuit (DgRL) for Improved Common Mode Rejection in Bio-Potential Acquisition Systems.

Guermandi M, Scarselli EF, Guerrieri R.

IEEE Trans Biomed Circuits Syst. 2016 Apr;10(2):507-17. doi: 10.1109/TBCAS.2015.2446753. Epub 2015 Aug 14.

PMID:
26285217
13.

Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.

Taylor G, Thom M, Capone S, Pierantoni A, Guzman E, Herbert R, Scarselli E, Napolitano F, Giuliani A, Folgori A, Colloca S, Cortese R, Nicosia A, Vitelli A.

Sci Transl Med. 2015 Aug 12;7(300):300ra127. doi: 10.1126/scitranslmed.aac5757.

PMID:
26268314
14.

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Del Sorbo M, Angus B, Siani L, Di Marco S, Traboni C, Folgori A, Colloca S, Capone S, Vitelli A, Cortese R, Klenerman P, Nicosia A, Pollard AJ.

Sci Transl Med. 2015 Aug 12;7(300):300ra126. doi: 10.1126/scitranslmed.aac5745.

15.

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.

Pierantoni A, Esposito ML, Ammendola V, Napolitano F, Grazioli F, Abbate A, Del Sorbo M, Siani L, D'Alise AM, Taglioni A, Perretta G, Siccardi A, Soprana E, Panigada M, Thom M, Scarselli E, Folgori A, Colloca S, Taylor G, Cortese R, Nicosia A, Capone S, Vitelli A.

Mol Ther Methods Clin Dev. 2015 May 20;2:15018. doi: 10.1038/mtm.2015.18. eCollection 2015.

16.

A novel minigene scaffold for therapeutic cancer vaccines.

Aurisicchio L, Fridman A, Bagchi A, Scarselli E, La Monica N, Ciliberto G.

Oncoimmunology. 2014 Jan 1;3(1):e27529. Epub 2014 Jan 16.

17.

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.

Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, La Monica N, Ciliberto G, Montero AJ.

J Transl Med. 2013 Mar 8;11:62. doi: 10.1186/1479-5876-11-62.

18.

A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.

Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto G, La Monica N, Aurisicchio L.

Mol Ther. 2010 Aug;18(8):1559-67. doi: 10.1038/mt.2010.104. Epub 2010 Jun 8.

19.

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V.

Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400.

20.

Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.

Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P, Bronte V.

Blood. 2010 Feb 18;115(7):1374-84. doi: 10.1182/blood-2009-07-233270. Epub 2009 Nov 10.

PMID:
19903903
21.

Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates.

Dharmapuri S, Peruzzi D, Mennuni C, Calvaruso F, Giampaoli S, Barbato G, Kandimalla ER, Agrawal S, Scarselli E, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L.

Mol Ther. 2009 Oct;17(10):1804-13. doi: 10.1038/mt.2009.165. Epub 2009 Jul 21. Erratum in: Mol Ther. 2010 Feb;18(2):447.

22.

Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.

Mennuni C, Ugel S, Mori F, Cipriani B, Iezzi M, Pannellini T, Lazzaro D, Ciliberto G, La Monica N, Zanovello P, Bronte V, Scarselli E.

Cancer Res. 2008 Dec 1;68(23):9865-74. doi: 10.1158/0008-5472.CAN-08-1603.

23.

Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy.

Cipriani B, Fridman A, Bendtsen C, Dharmapuri S, Mennuni C, Pak I, Mesiti G, Forni G, Monaci P, Bagchi A, Ciliberto G, La Monica N, Scarselli E.

Hum Gene Ther. 2008 Jul;19(7):670-80. doi: 10.1089/hum.2007.127.

PMID:
18533895
24.

Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.

Iero M, Squarcina P, Romero P, Guillaume P, Scarselli E, Cerino R, Carrabba M, Toutirais O, Parmiani G, Rivoltini L.

Cancer Immunol Immunother. 2007 Dec;56(12):1979-91. Epub 2007 Jun 13.

PMID:
17564703
25.

CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand.

Salucci V, Mennuni C, Calvaruso F, Cerino R, Neuner P, Ciliberto G, La Monica N, Scarselli E.

Scand J Immunol. 2006 Jan;63(1):35-41.

26.

Adenovirus transduction and culture conditions affect the immunogenicity of murine dendritic cells.

Salucci V, Lena AM, Ciliberto G, Scarselli E, La Monica N.

Scand J Immunol. 2005 Sep;62(3):206-17.

27.

Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA.

Mennuni C, Calvaruso F, Facciabene A, Aurisicchio L, Storto M, Scarselli E, Ciliberto G, La Monica N.

Int J Cancer. 2005 Nov 10;117(3):444-55.

28.

Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes.

Barth H, Cerino R, Arcuri M, Hoffmann M, Schürmann P, Adah MI, Gissler B, Zhao X, Ghisetti V, Lavezzo B, Blum HE, von Weizsäcker F, Vitelli A, Scarselli E, Baumert TF.

J Virol. 2005 May;79(9):5774-85.

29.

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL.

J Biol Chem. 2003 Oct 24;278(43):41624-30. Epub 2003 Aug 11.

30.

Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.

Roccasecca R, Ansuini H, Vitelli A, Meola A, Scarselli E, Acali S, Pezzanera M, Ercole BB, McKeating J, Yagnik A, Lahm A, Tramontano A, Cortese R, Nicosia A.

J Virol. 2003 Feb;77(3):1856-67.

31.

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A.

EMBO J. 2002 Oct 1;21(19):5017-25.

32.

Generation of infectious and transmissible virions from a GB virus B full-length consensus clone in tamarins.

Sbardellati A, Scarselli E, Verschoor E, De Tomassi A, Lazzaro D, Traboni C.

J Gen Virol. 2001 Oct;82(Pt 10):2437-48.

PMID:
11562537
33.

Processing of GB virus B non-structural proteins in cultured cells requires both NS3 protease and NS4A cofactor.

Sbardellati A, Scarselli E, Amati V, Falcinelli S, Kekulé AS, Traboni C.

J Gen Virol. 2000 Sep;81(Pt 9):2183-8.

PMID:
10950975
34.

Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection.

Meola A, Sbardellati A, Bruni Ercole B, Cerretani M, Pezzanera M, Ceccacci A, Vitelli A, Levy S, Nicosia A, Traboni C, McKeating J, Scarselli E.

J Virol. 2000 Jul;74(13):5933-8.

35.

Identification of a novel sequence at the 3' end of the GB virus B genome.

Sbardellati A, Scarselli E, Tomei L, Kekulé AS, Traboni C.

J Virol. 1999 Dec;73(12):10546-50.

36.

GB virus B and hepatitis C virus NS3 serine proteases share substrate specificity.

Scarselli E, Urbani A, Sbardellati A, Tomei L, De Francesco R, Traboni C.

J Virol. 1997 Jul;71(7):4985-9.

37.

Recombinant human antibodies specific for hepatitis C virus proteins.

Esposito G, Morea V, Scarselli E, Cerino A, Mondelli MU, La Monica N, Traboni C.

Arch Virol. 1997;142(3):601-10.

PMID:
9349306
38.

A human antibody specific for hepatitis C virus core protein: synthesis in a bacterial system and characterization.

Esposito G, Scarselli E, Cerino A, Mondelli MU, La Monica N, Traboni C.

Gene. 1995 Oct 27;164(2):203-9.

PMID:
7590332
40.

Phage display of a human antibody against Clostridium tetani toxin.

Esposito G, Scarselli E, Traboni C.

Gene. 1994 Oct 11;148(1):167-8.

PMID:
7926831
41.
42.

Analysis of the human antibody response to thrombospondin-related anonymous protein of Plasmodium falciparum.

Scarselli E, Tolle R, Koita O, Diallo M, Müller HM, Früh K, Doumbo O, Crisanti A, Bujard H.

Infect Immun. 1993 Aug;61(8):3490-5.

43.

Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum in parasite-host cell interactions.

Müller HM, Scarselli E, Crisanti A.

Parassitologia. 1993 Jul;35 Suppl:69-72.

PMID:
8233617
44.

Selective deficiency of CD4+/CD45RA+ lymphocytes in patients with ataxia-telangiectasia.

Paganelli R, Scala E, Scarselli E, Ortolani C, Cossarizza A, Carmini D, Aiuti F, Fiorilli M.

J Clin Immunol. 1992 Mar;12(2):84-91.

PMID:
1373152
45.

Clonally expanded CD3+, CD4-, CD8- cells bearing the alpha/beta or the gamma/delta T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytes.

Pandolfi F, Foa R, De Rossi G, Zambello R, Chisesi T, di Celle PF, Migone N, Casorati G, Scarselli E, Ensoli F, et al.

Clin Immunol Immunopathol. 1991 Sep;60(3):371-83.

PMID:
1830831
46.

Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes.

Zambello R, Pizzolo G, Trentin L, Agostini C, Chisesi T, Vinante F, Scarselli E, Zanotti R, Vespignani M, De Rossi G, et al.

Cancer. 1989 Nov 15;64(10):2019-23.

PMID:
2804889
47.

HTLV-I antibodies and lymphoproliferative disease of granular lymphocytes.

Pandolfi F, Shriver K, Scarselli E, Fiorelli V, Semenzato G, Zambello R, Chisesi T, de Rossi G, Strong DM.

Lancet. 1987 Dec 26;2(8574):1527. No abstract available.

PMID:
2892087
48.
49.

Reduction of circulating suppressor inducer T lymphocytes in the exacerbation phase of remitting-relapse multiple sclerosis.

Cafaro A, Spadaro M, Pandolfi F, Tilia G, Scarselli E, Liberati F, Aiuti F.

Riv Neurol. 1987 May-Jun;57(3):159-62.

PMID:
2960006
50.

[When may aged persons drink coffee?].

Scarselli E.

Minerva Med. 1972 Sep 5;63(61):3335-9. Italian. No abstract available.

PMID:
5055843

Supplemental Content

Loading ...
Support Center